Navigation Links
Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference
Date:3/10/2010

CORAL GABLES, Fla., March 10 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced that Patrick J. McEnany, Catalyst's Chief Executive Officer, will be making a presentation at the BioNetwork East 2010 Conference to be held March 15th through March 17th at the Eden Roc Resort and Spa on Miami Beach.  Catalyst will present a Corporate Overview, including its development plans for CPP-109 and CPP-115. Further, the Company reported that its presentation materials from the conference will be posted on March 16th on the Company's website, www.catalystpharma.com, under "Events and Presentations."

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. The Company has obtained from Brookhaven National Laboratory an exclusive license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also in-licensed worldwide rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. CPP-109, Catalyst's version of vigabatrin, has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction.  Catalyst has also recently in-licensed worldwide rights to another patented drug, CPP-115, from Northwestern University. The Company intends to pursue development of CPP-115 for several indications, including epilepsy and drug addiction.  For more information about the Company, go to www.catalystpharma.com.

SOURCE Catalyst Pharmaceutical Partners, Inc.

Back to top

RELATED LINKS
http://www.catalystpharma.com

'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
10. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
11. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...
(Date:12/8/2016)... FLINT, Mich. , Dec. 8, 2016  Diplomat Pharmacy, Inc. ... as a 2016 Top Workplaces National Standard. ... . ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... are based on an employee survey administered by WorkplaceDynamics, LLC, a ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I have gout, and I wanted to ... recipe, which is meant to relieve gout and pain caused by varicose veins. I ... boost every time. It relieved what VA doctors called the worst sinusitis case they'd ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted to ... types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. ... and could be set up in a matter of minutes, or even seconds. The ...
(Date:12/9/2016)... ... 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated patient ... solution for Emergency Departments (ED) has been added to their portfolio. Housed in ... rooms, and with a simplified pallet of information available to the patient, the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
Breaking Medicine News(10 mins):